Low-dose bevacizumab plus adebrelimab with TACE-HAIC for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination treatment for liver cancer that cannot be removed with surgery. It combines targeted therapy and immunotherapy with a procedure that delivers chemotherapy directly to the liver, aiming to shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with hepatocellular carcinoma (the most common type of liver cancer).
- Your liver cancer cannot be removed with surgery, but it has not spread to the main vein in the liver or to other parts of the body.
- You have not received any prior treatment for your liver cancer (like chemotherapy or targeted pills).
- You are generally able to take care of yourself (ECOG score 0 or 1).
- Your liver function is relatively good (Child-Pugh score A or B7).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study combines a liver-directed procedure called TACE (which blocks blood flow to the tumor and delivers chemotherapy directly to it) with two immunotherapy drugs and a targeted therapy (bevacizumab). The goal is to see if this combination can shrink liver cancer that cannot be surgically removed, without the cancer having spread elsewhere.
This trial tests whether combining TACE (a liver-targeted chemo procedure) with two medicines—an immune “checkpoint” drug and a blood-vessel blocking drug—can control unresectable hepatocellular carcinoma. It’s designed for people who can’t have surgery or curative ablation, and who still have reasonably strong liver and overall health.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This study tests a new combination treatment for liver cancer that cannot be removed by surgery. It combines a procedure called TACE (which delivers chemotherapy directly to the tumor) with an investigational drug, ivonescimab, which helps the immune system fight cancer. The goal is to see if this combination is safe and effective for people whose cancer has not spread beyond the liver.
This trial tests a combination of local treatments (like TACE or HAIC) with bevacizumab and an immunotherapy drug (PD-1/L1 inhibitor) for advanced liver cancer. It may be an option if you haven't had systemic therapy before or if your previous treatment stopped working.
This trial tests a combination of an immunotherapy drug (adebrelimab) and a targeted therapy (bevacizumab) given through a vein or directly into the liver artery, along with standard chemotherapy directly into the liver artery, for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this approach can shrink or control the cancer.
Hear when a new Adebrelimab (SHR-1316) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.